We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0K2H market cap is 760.16M. The company's latest EPS is USD -0.9986 and P/E is -1.78.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -17.52M | -19.74M | -22.97M | -30.64M | -29.63M |
| Net Income | -13.21M | -17.36M | -15.89M | -29.03M | -29.77M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 25.24M | 29.03M | 84.09M | 57.42M | 38.22M |
| Total Liabilities | 9.66M | 11.27M | 5.1M | 5.23M | 12.14M |
| Total Equity | 15.57M | 17.76M | 78.99M | 52.19M | 26.07M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.2M | -17.77M | -18.95M | -27.64M | -24.1M |
| Investing | -51k | -374k | -19k | -67k | -124k |
| Financing | 20.85M | 22.55M | 74.72M | -23k | 4.65M |
| Market Cap | 760.16M |
| Price to Earnings Ratio | -1.78 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.25 |
| Price to Book Ratio | 2.04 |
| Dividend Yield | - |
| Shares Outstanding | 29.81M |
| Average Volume (1 week) | 64 |
| Average Volume (1 Month) | 152 |
| 52 Week Change | 0.00% |
| 52 Week High | 25.50 |
| 52 Week Low | 25.50 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Moleculin Biotech Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.moleculin.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
